Rivaroxaban: Difference between revisions
No edit summary |
|||
| Line 8: | Line 8: | ||
{{SB}} XARELTO<sup>®</sup> | {{SB}} XARELTO<sup>®</sup> | ||
[[riva1.png|800px]] | |||
==Overview== | ==Overview== | ||
'''Rivaroxaban''' (BAY 59-7939) is an [[route of administration|oral]] [[anticoagulant]] invented and manufactured by [[Bayer]]; in a number of countries it is marketed as '''Xarelto'''.<ref name="Xarelto SPC">{{cite web |url=http://www.xarelto.com/scripts/pages/en/information-on-xarelto/summary_of_product_characteristics/index.php |title=Xarelto: Summary of Product Characteristics |publisher=Bayer Schering Pharma AG |year=2008 |accessdate=2009-02-11}}</ref> In the United States, it is marketed by [[Janssen Pharmaceutica]].<ref name="US Approval">{{cite press release |title=FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery |publisher=[[Janssen Pharmaceutica]] |date=2011-07-01 |url=http://m.prnewswire.com/news-releases/fda-approves-xarelto-rivaroxaban-tablets-to-help-prevent-deep-vein-thrombosis-in-patients-undergoing-knee-or-hip-replacement-surgery-124872829.html |accessdate=2011-07-01}}</ref> It is an orally active [[direct factor Xa inhibitor]]. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8 to 12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible. | '''Rivaroxaban''' (BAY 59-7939) is an [[route of administration|oral]] [[anticoagulant]] invented and manufactured by [[Bayer]]; in a number of countries it is marketed as '''Xarelto'''.<ref name="Xarelto SPC">{{cite web |url=http://www.xarelto.com/scripts/pages/en/information-on-xarelto/summary_of_product_characteristics/index.php |title=Xarelto: Summary of Product Characteristics |publisher=Bayer Schering Pharma AG |year=2008 |accessdate=2009-02-11}}</ref> In the United States, it is marketed by [[Janssen Pharmaceutica]].<ref name="US Approval">{{cite press release |title=FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery |publisher=[[Janssen Pharmaceutica]] |date=2011-07-01 |url=http://m.prnewswire.com/news-releases/fda-approves-xarelto-rivaroxaban-tablets-to-help-prevent-deep-vein-thrombosis-in-patients-undergoing-knee-or-hip-replacement-surgery-124872829.html |accessdate=2011-07-01}}</ref> It is an orally active [[direct factor Xa inhibitor]]. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8 to 12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible. | ||
Revision as of 14:16, 3 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
For patient information, click here. Synonyms / Brand Names: XARELTO®
Overview
Rivaroxaban (BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto.[1] In the United States, it is marketed by Janssen Pharmaceutica.[2] It is an orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8 to 12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
Category
Direct Xa factor inhibitor.
FDA Package Insert
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
References
- ↑ "Xarelto: Summary of Product Characteristics". Bayer Schering Pharma AG. 2008. Retrieved 2009-02-11.
- ↑ "FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery" (Press release). Janssen Pharmaceutica. 2011-07-01. Retrieved 2011-07-01.